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Abstract  
 
Background  
Post stroke spasticity (PSS) occurs approximately in 30% of stroke survivors. Spasticity varies from 
a subtle neurological sign to a gross increase in tone causing immobility of joints. PSS is associated 
with several complications, increasing care needs and utilisation of healthcare resources. 
Botulinum toxin type A (BoNT-A) has been considered as an effective and safe treatment for focal 
spasticity in stroke survivors, with low prevalence of complications, reversibility of effect, and 
efficacy in reducing spastic hypertonia. Recent studies estimated that a significant percentage of 
patients affected by PSS could benefit from higher doses than those permitted by current country 
directives. However, at present time, there is no general consensus on the maximum dose of BoNT-
A in terms of safety and clinical interchangeability among the three commercially approved products 
(abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA).  
In light of these considerations, the aim of this thesis is to investigate the safety profile of BoNT-A 
high doses in the treatment of post stroke spasticity.  
In our research activity we investigated the clinical effect of this treatment in severely affected 
patients, focusing on both clinical and instrumental assessment of systemic effects of BoNT-A. 
  
Results  
Although systemic BoNT-A toxicity is a rare event and as such not necessarily fatal, fear of systemic 
toxicity is still the most vigorous concern against application of increased BoNT-A doses.  
Current evidence coming from published literature, considering both clinical and instrumental 
analysis of BoNT-A systemic diffusion, suggests that higher doses of BoNT-A are efficacious in 
reducing spasticity of the upper and lower limbs after stroke, with rare occurence of mild adverse 
effect.  
 
Conclusions  
The evidence coming from published studies suggests that use of doses of BoNT-A higher than those 
reported in product labels could be considered as a safe therapeutic option to reduce multifocal or 
generalized post stroke spasticity in selected patients. The clinicians have to carefully define the 
clinical goal before starting with BoNT-A treatment, considering all the factors which could affect 
the safety profile of BoNT-A. 
Further evidence is mandatory to confirm higher doses of BoNT-A as a safe and effective therapeutic 
option for the treatment of post stroke spasticity. In particular, it should be pointed out the potential 
role of higher doses of BoNT-A in order to improve the functional outcome of these patients. 
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Riassunto  
 
 
Introduzione 
La spasticità post ictus (PSS) è osservata in circa il 30% dei soggetti con esiti di stroke.  
La presentazione può variare da un lieve incremento del tono muscolare ad una immobilizzazione di 
segmenti articolari, ed è causa di significative complicanze e di incremento di costi assistenziali e 
sanitari. 
La tossina botulinica di tipo A (BoNT-A) è un trattamento sicuro ed efficace nel trattamento della 
PSS focale. Da studi recenti emerge che una significativa percentuale di pazienti potrebbe trarre 
benefici dall’utilizzo di dosi di BoNT-A superiori a quelle indicate in scheda tecnica. Tuttavia, non 
vi sono attualmente pareri unanimi in merito alla massima dose utilizzabile ed alla intercambiabilità 
fra le BoNT-A in commercio (abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA). 
Obiettivo della tesi è la valutazione del profilo di sicurezza delle alte dosi di BoNT-A nel trattamento 
della PSS. Nella nostra attività di ricerca abbiamo analizzato l’effetto clinico di questo trattamento in 
pazienti affetti da PSS severa multifocale; particolare attenzione è stata rivolta alla valutazione clinica 
e strumentale degli effetti sistemici di BoNT-A.  
 
Risultati 
La tossicità sistemica è un evento raro e non sempre fatale, ma il timore della sua insorgenza è tuttora 
la maggiore criticità legata all’applicazione di alte dosi di BoNT-A.  
Le attuali evidenze, che considerano sia una valutazione clinica che una valutazione strumentale della 
diffusione sistemica di BoNT-A, suggeriscono che alte dosi di BoNT-A sono efficaci nella riduzione 
della PSS all’arto superiore ed inferiore, con una bassa incidenza di effetti avversi.  
 
Conclusioni 
Le attuali evidenze suggeriscono che l’utilizzo di dosi di BoNT-A superiori a quelle indicate in scheda 
tecnica possono essere considerate come un’opzione terapeutica sicura ed efficace nel trattamento di 
PSS in pazienti selezionati.  I clinici devono definire con accuratezza gli obiettivi terapeutici, 
considerando tutti i fattori che possono influenzare il profilo di sicurezza del farmaco. Ulteriori 
evidenze sono necessarie per confermare il profilo di efficacia e sicurezza delle alte dosi di BoNT-A 
nel trattamento della spasticità focale post ictus. Particolare attenzione deve essere rivolta a definire 
il ruolo delle alte dosi di BoNT-A nel miglioramento dell’outcome funzionale del paziente.  
 
 
 5 
Introduction 
 
Stroke-related disability is a significant health problem with relevant socioeconomic consequences 
for patients as well as society with long-lasting effects.  
More than two-thirds of stroke survivors develop poststroke sequelae, including impaired motor 
function and spasticity. These impairments have a significant impact on a stroke survivor’s daily life, 
such as eating, walking and self-care. In addition, these disabilities involve a significant burden on 
caregivers of these patients [Wissel et al, 2013].  
Post stroke spasticity (PSS) occurs approximately in 30% of stroke survivors. Spasticity varies from 
a subtle neurological sign to a gross increase in tone causing immobility of joints. PSS is associated 
with several complications, increasing care needs and utilisation of healthcare resources [Lundstrom 
et al 2010], and carers of patients with spasticity are more likely to experience anxiety and depression 
[Denno et al, 2013]. 
Management of spasticity requires a balanced approach, weighing the benefits of treatment against 
the side effects.  
Botulinum toxin type A (BoNT-A) has been considered as an effective and safe treatment for focal 
spasticity in stroke survivors, with low prevalence of complications, reversibility, and efficacy in 
reducing spastic hypertonia [Santamato et al, 2015], with the approval of the U.S. Food and Drug 
Administration and the European regulatory agencies for this indication. However, at present time, 
there is no general consensus on the maximum dose of BoNT-A in terms of safety and clinical 
interchangeability among the three commercially approved products (abobotulinumtoxinA, 
onabotulinumtoxinA, incobotulinumtoxinA).  
A recent survey [Picelli A, Baricich A et al, 2017] suggested that there is a need to reconsider the 
maximum dose administered per single treatment in order to improve the clinical outcome of treated 
patients. In fact, the use of high doses of BoNT-A is an established practice that, moreover, addresses 
the very real need to improve the quality of life of patients with post-stroke spasticity [Baricich et al., 
2015]. It has been reported that a high percentage of patients (up to about 62%) needs a combined 
BoNT-A treatment of upper and lower limb, while only a very low proportion (< 25% on average) 
requires treatment in the upper or lower limb alone in a single session; in addition, anecdotal, 
unpublished, 10- year follow-up observations showed that a tendency to increase BoNT-A doses over 
time was paralleled by a tendency of patients to be more satisfied [Picelli A, Baricich A et al, 2017].  
However, the most important adverse effect of BoNT-A is the systemic diffusion of the toxin and it 
has been suggested [Lange et al, 1987] a potential relationship with BoNT-A dose, causing a possible 
increase of adverse events after injection.    
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Aim of the thesis 
In light of these considerations, the aim of this thesis is to investigate the safety profile of BoNT-A 
high doses in the rehabilitation treatment of post stroke spasticity, focusing on both clinical and 
instrumental assessment of systemic effects of BoNT-A.  
Presentation of data derived from published studies will be integrated with the findings obtained by 
our group.   
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Post stroke spasticity 
 
The term spasticity as a clinical entity was proposed by J.W. Lance in the 1980s as “a motor disorder 
characterized by a velocity-dependent increase in tonic stretch reflex (muscle tone) with exaggerated 
tendon jerks, resulting from hyperexcitability of the stretch reflex as one component of the upper 
motor neuron syndrome (UMNS)”. In clinical practice, spasticity describes a combination of 
symptoms and clinical signs after lesion formation in sensorimotor brain areas and tracts in the 
Central Nervous System (CNS), resulting from impaired reflex function; In addition, spasticity 
induces changes in rheological muscle properties like stiffness, fibrosis and atrophy [Dietz and 
Sinkjaer, 2007].  
There is still no consensus for the definition of spasticity and this reflects the complexity and the 
diversity of the phenomena [Baricich et al, 2016; Picelli A, Vallies G et al, 2017]. This is especially 
true for post-stroke motor disorders, which can show a considerable variety of symptoms (e.g. clonus, 
dystonia, muscle weakness, abnormal reflex responses).  
In general, the ‘upper motor neuron syndrome’ can be defined by the presence of positive and 
negative signs [Young, 1994]. Spasticity is part of the positive signs among other motor symptoms 
which occur after lesions in the descending corticospinal system such as spastic dystonia (muscle 
constriction in the absence of any voluntary movement), spastic co-contraction (contraction of both 
the agonist and antagonist muscles resulting from an abnormal pattern of commands in the descending 
supraspinal pathway), extensor or flexor spasms, clonus, exaggerated deep tendon reflexes and 
associated reaction [McComas, 1994; Sommerfeld et al, 1994]. On the other hand, negative signs are 
muscle weakness, loss of dexterity and fatigue.  
Prevalence estimates of post stroke spasticity (PSS) were highly variable, ranging from 4% to 42.6%, 
with the prevalence of disabling spasticity ranging from 2% to 13%. Data on phases of the PSS 
continuum revealed evidence of PSS in 4% to 27% of those in the early time course (1–4 weeks post 
stroke), 19% to 26.7% of those in the postacute phase (1–3 months post stroke), and 17% to 42.6% 
of those in the chronic phase (>3 months post stroke) [Wissel et al, 2013].  
In the upper limbs, the most frequently observed pattern is internal rotation and adduction of the 
shoulder coupled with flexion at the elbow, the wrist and the fingers; in the lower limbs, adduction 
and extension of the knee with equinovarus foot [Thibaut et al, 2013].  
Spastic symptoms can induce pain, ankylosis, tendon retraction or muscle weakness in patients, which 
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can limit the success of rehabilitation. Spasticity can also affect quality of life and be highly 
detrimental to daily function [Duncan et al, 2005; Langhorne, 2011; Chae and Celnik, 2015]. 
However, there is currently a lack of specific guidelines for the stratification and individualization of 
rehabilitation programmes [Thibaut, 2013; Picelli A, Baricich A et al, 2017].  
Therapeutic interventions include physical therapy, occupational therapy, self-rehabilitation, orthoses 
equipment and assistive devices, pharmacological treatment, orthopaedic surgery and neurosurgery 
[Thibaut et al, 2013; Deltombe et al, 2017].  
 
Botulinum Toxin and post stroke spasticity  
Botulinum Toxin type A (BoNT-A) administered by intramuscular injection, is the gold standard for 
the treatment of focal spasticity, with low prevalence of complications, reversibility, and efficacy in 
reducing spastic hypertonia with the approval of the U.S. Food and Drug Administration and the 
European regulatory agencies for this indication.  
BoNT-A showed to increase patient’s ability to actively mobilize their upper and lower limbs and 
improve their autonomy (e.g. self-care, walking) [Thibaut et al, 2013; Simpson et al, 2016]. 
 
Pharmacology and immunology of Botulinum Toxin  
Botulinum neurotoxin (BoNT) is a microbial protein which exists in seven different serotypes, 
designated A through G. Although the individual serotypes are immunologically distinct, all members 
of the group present similar subunit structures, act on the same target organs, and produce similar 
functional outcomes [Lacy and Stevens, 1999; Johnson and Bradshaw, 2009]. Each molecule is 
typically released from bacteria as part of a noncovalent complex with other associated proteins. 
These auxiliary proteins do not play an active role in the therapeutic actions of the toxin, even if it 
was hypothesized a possible involvement in undesirable effects.  
BoNT is an enzyme which acts in the cytosol of nerve endings: it cleaves three polypeptides 
governing exocytosis. Serotypes A and E cleave synaptosomal-associated protein (SNAP)-25, 
serotypes B, D, F, and G cleave vesicle-associated membrane protein (VAMP), and serotype C 
cleaves both syntaxin and SNAP-25 [Simpson, 2004; Humeau et al, 2000]. 
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The block of acetylcholine release at neuro-muscular junctions is the mechanism involved in the 
therapeutic effect of BoNT to relieve dystonia, spasticity, and related disorders [Tassorelli et al, 
2006].  
BoNT showed additional therapeutic benefits, not necessarily related to neuromuscular transmission, 
including blockade of acetilcholine release at autonomic nerve endings and blockade of transmitter 
release at peripheral nerve endings that use other mediators. 
In addition to peripheral effects of BoNT, indirect effects on CNS have been observed, probably 
resulting from changes in the normal balance of efferent and afferent signals. Interestingly, both the 
direct and indirect actions of the toxin are largely or completely reversible [Simpson et al, 2008].  
At the present time, BoNT is commercially available in 2 serotypes, A and B. In United States, Food 
and Drug Administration approved four preparations of BoNT: onabotulinumtoxinA (Botox®, 
Allergan, Inc., United States), abobotulinumtoxinA (Dysport®, Ipsen, France), incobotulinumtoxinA 
(Xeomin®, Merz Pharmaceuticals GmbH, Germany), and rimabotulinumtoxinB 
(Myobloc/Neurobloc® (US WorldMeds/Solstice Neurosciences, United States). [Table 1] 
 
Table 1: Botulinum toxins and FDA-approved indications (modified from Simpson et al, 2016) 
BoNT preparation Brand name (manufacturer) FDA approved indications 
OnabotulinumtoxinA Botox (Allergan, Inc., Irvine, CA) 
Blepharospasm, cervical dystonia, 
upper extremity spasticity, lower 
extremity spasticity, chronic 
migraine, treatment of urinary 
incontinence due to detrusor 
overactivity, axillary 
hyperhidrosis, strabismus 
AbobotulinumtoxinA Dysport (Ipsen Ltd., Paris, France) Cervical dystonia, spasticity 
IncobotulinumtoxinA Xeomin (Merz Pharmaceuticals, Frankfurt, Germany) 
 
Blepharospasm, cervical dystonia, 
upper extremity spasticity 
 
 
RimabotulinumtoxinB 
 
Myobloc/Neurobloc (US 
WorldMeds/Solstice 
Neurosciences, Louisville, KY) 
Cervical dystonia 
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BoNT-A is approved for cervical dystonia and spasticity, whereas BoNT-B was approved for cervical 
dystonia only.  
In nature, BoNT-A is synthesized as macromolecular protein complexes [Aoki and Guyer, 2001]. 
These protein complexes are referred to as progenitor toxins and consist of nontoxic accessory 
proteins (NAPs) bonded to the 150-kD active neurotoxin.  
The BoNT-A progenitor toxins vary in molecular weight (300–900 kD) depending on the 
composition of NAPs and the manufacturing process [Dressler and Benecke, 2007]. The 150-kD 
neurotoxin must dissociate from NAPs in order to exert its pharmacologic effects. This dissociation 
occurs in physiologic pH conditions.  
Although no clear differences in effectiveness between the various formulations were demonstrated, 
their comparability is still intensely debated, focusing on several issues such as potency, dose 
equivalence, immunogenicity, spread and systemic diffusion.  
 
Potency  
Although the various BoNT-A products differ in NAP composition, the 150-kD neurotoxin is the 
active part inhibiting acetylcholine release.  
Since the toxin moiety is the same in all pharmaceutical preparations, differences in potency could 
depend of the amount of active toxin available. To become fully activated, the single chain 150-kD 
neurotoxin must be cleaved from the protein complex. All of the commercially available BoNT-A 
formulations are composed of the 150-kD neurotoxin with NAPs; the only exception is 
incobotulinumtoxinA, which contains only the 150-kD neurotoxin.  
However, also the manufacturing process may affect the amount of active toxin; for instance, 
enzymes added to increase the percentage of cleaved active toxin may denature the neurotoxic protein 
itself.  
BoNT-A formulations contain different percentages of inactive toxin which contribute to the overall 
protein load. For this reason, the potency is expressed in biological units. Potency is related to the 
quantity of toxin (in ng of protein content, i.e., 150 kD neurotoxin including NAPs) required to 
achieve a median lethal dose (LD50) unit [Sesardic et al, 2003; McLellan et al, 1996]. However, 
many factors affect the mouse LD50 bioassay including mouse strain, sex, age, volume and route of 
injection, time of examination after injection, and delivery vehicle or reconstituting buffer. Moreover, 
the LD50 units of BoNT products are not standardized across manufacturers.  
Due to the lack of LD50 bioassay harmonization, the unit potencies of BoNT formulations cannot 
easily be compared. For this reason, it is mandatory that physicians consider that, even if the active 
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molecule is botulinum neurotoxin type A, different forms of the complex can affect the therapeutic 
profiles. In fact, as prevously described, there are several BoNT-A products on the market: 
onabotulinumtoxinA (ONA), incobotulinumtoxinA (INCO) and abobotulinumtoxinA (ABO) 
[Albanese, 2011].  
However, despite the difficulties related to the biologic units, the most informative comparisons of 
BoNT-A products have been made in clinical studies.  
 
Dose equivalence 
Each BoNT-A formulation contains different amounts of the 150-kD toxin (and NAPs)/LD50 unit 
(Table 2). However, although there are some difficulties establishing the comparative potencies, the 
equivalence ratio of the dose should be established.  
There are several reasons for identifying a conversion factor: medical (i.e., patients may need to 
switch to another formulation) as well as economical (an incorrect conversion factor may negatively 
impact the real cost of treatment) [Chen and Dashtipour, 2013; Frevert, 2015].  
 
Table 2: Botulinum toxin products and protein content/100 units (Adapted from Scaglione, 2016) 
BoNT-A 150-kD protein content (ng) 
Total protein content 
(150 kD and NAP) (ng) Dose Equivalent Units 
OnabotulinumtoxinA 0.73 5.00 1 
IncobotulinumtoxinA 0.44 0.44 1 
AbobotulinumtoxinA 0.65 0.87 2-3 
NAP: nontoxic accessory proteins  
 
INCO has been shown to be as effective as ONA with a comparable adverse event profile with a 
clinical conversion ratio of 1:1 or 1:1.2 [Benecke et al, 2005; Roggenkamper et al, 2006; Jost et al, 
2005; Park et al, 2011; Zoons et al, 2012]. Clinical results are consistent with preclinical 
comparability data [Dressler and Benecke, 2007; Dressler et al, 2012]. Thus, both clinical and 
preclinical analyses have demonstrated a clinical conversion ratio between ONA and INCO very 
close to 1:1.  
In contrast, the conversion ratio between ONA (or INCO, consequently) and ABO is highly debated. 
Even if the most commonly used conversion ratios are 1:3 or 1:4 [Aoki et al, 2006], they ranged from 
1:1 [Wohlfarth et al, 2007] to as high as 1:11 [Marchetti et al, 2005]. This wide conversion ratio range 
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reflects real-life clinical practice; the treating physician determines the number of muscles to be 
treated and the empiric dose based on each patient’s conditions, their clinical pattern, and treatment 
goals.  
Although the various BoNT products differ in NAP composition, the toxins ultimately inhibit 
acetylcholine release. Since the active toxin content is established for each product, a conversion rate 
should be defined. More precise estimation of conversion ratios should also ensure the development 
of comparable clinical data on the efficacy and safety of currently available BoNT-A formulations 
since they have qualitatively and quantitatively similar clinical efficacies and side effects at 
equipotent doses.  
A large number of studies have reported an ONA:ABO conversion factor of 1:3 with  clinical 
equivalence [Marion et al, 1995; Whurr et al, 1995; Kollewe et al, 2010; Odergren et al, 1998; Shin 
et al, 2009]. Moreover, when the conversion factor is close to 1:3, ABO showed higher efficacy 
[Wohlfarth et al, 2008; Mohammadi et l, 2009; Rystedt et al, 2012], indicating that the conversion 
factor could be rather lower than equal to 1:3. Interestingly, studies where the conversion ratio was 
higher than 1:3 showed higher efficacy and longer duration of action of ABO compared to ONA, but 
with more adverse events, supposing an overdose of ABO determined by this conversion ratio 
[Sampaio et al, 1997; Nussgens et al, 1997; Ranoux et al, 2002; Bentivoglio et al, 2012].  
These clinical data are consistent with preclinical data where a conversion ratio for ONA/ABO of 1:3 
or lower has been found [Van den Berg an Lison, 1998; Rosales et al, 2006; Wohlfarth et al, 2009; 
Keren-Capelovitch et al, 2010, Brockmann et al, 2012; Kollewe et l, 2015; Rystedt et al, 2015; Yun 
et al, 2015; Hambleton and Pickett, 1994].  
In conclusion, current data suggest that a conversion ratio ONA/ABO of 1:3—or even lower—is 
appropriate for treating spasticity, cervical dystonia, and blepharospasm or hemifacial spasm. A 
higher conversion ratio may lead to an excessive ABO dose (with the potential for an increased 
incidence of adverse events) or underdosing when switching ABO to ONA [Scaglione, 2016].  
 
Immunogenicity 
A possible reason for secondary treatment failure of any therapeutic protein is its neutralization 
[Kromminga and Schellekens, 2005]. Antibodies that block its pharmacological effects are termed 
neutralizing antibodies, addressed against the active toxin. In this case, the clinical effect may wane 
gradually, eventually leading to complete treatment failure.  
In a study of 27 patients with complete treatment failure due to neutralizing antibodies, the majority 
(81%) of patients had previously experienced partial antibody-induced treatment failure [Dressler, 
2002]. Most patients in this study developed treatment failure within 40 months of starting BoNT 
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treatment.  
However, another study reported a high mean clinical benefit similar for ABO and ONA and <2% of 
the patients developed neutralizing antibodies [Mohammadi et al, 2009].  
However, in more recent investigations, BoNT-A antibodies were not detected [Bakheit et al, 2012; 
Wissel et al, 2017].  
The debate regarding immunogenicity includes the role of the non-toxic proteins, collectively referred 
to as complexing proteins or neurotoxin-associated proteins (NAPs). Under physiological pH 
conditions, the complexing proteins dissociate from the neurotoxin after constitution with saline and 
even before injection [Eisele et al, 2011; Benecke, 2012]. Complexing proteins are not expected to 
modify clinical outcomes, and specific antibodies generated against the complexing proteins are 
termed non-neutralizing and should not affect the secondary response. However, it has been argued 
that complexing proteins may increase the bacterial protein load and could potentially increase the 
immunogenic risk of neutralizing antibody formation [Kukreja et al, 2009]. Even if several studies 
have been conducted, there are no clear demonstrations that NAPs modify the immunogenicity of the 
active toxin [Atassi, 2004; Atassi, 2006; Bigalke, 2009]. However, these studies revealed that the 
toxoid complex is more immunogenic than the purified neurotoxin. This could be relevant 
considering that cross-reactivity may occur between the toxoid and toxin. However, despite the 
considerations mentioned above, the risk of immunogenicity of BoNT-A is very low in clinical 
practice as reported by a large data review [Jankovic et al, 2004; Wissel et al, 2017].  
 
BoNT and systemic diffusion 
BoNT ability to remain relatively localized at the site of injection is largely responsible for its 
remarkable safety profile.  In general, spread and diffusion are supposed to underlie most of the local, 
distal, and systemic effects of BoNT [Ramirez-Castaneda et al, 2013]. 
BoNT spread (also called diffusion) describes the toxin’s effect on areas away from the injection site. 
The potential risk for adverse effects due to toxin spread is described in the labeling for each BoNT-
A product [Scaglione, 2016]. However, the mechanism of this phenomenon is not completely 
understood.  
Spread to contiguous areas could increase the risk of adverse effects. For example, spread from 
injections in the cervical or craniofacial musculature may induce diplopia, dysarthria, or dysphagia, 
whereas injections in extremities could induce weakness in non-treated, close muscles.  
Although uncommon, distant spread can occur, causing unintended neuromuscular blockade remote 
to the injection site. For example, systemic botulism symptoms such as dysphagia can occur when 
the toxin is injected at a distant site (e.g., lower extremities for spasticity). Even if generalized 
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weakness is a rare occurrence after BoNT injections, Bhatia and colleagues reported the case of three 
patients who developed generalized muscle weakness, drawing attention to the rare possibility of 
mild botulism after treatment with BoNT-A for dystonia [Bhatia et al, 1999]. Moreover, flu-like 
symptoms (another possible sign of distant spread or a systemic immune response) vary widely in 
different studies: 1.7% to 20% of patients treated with various preparations of BoNT-A, and 5% to 
55% of patients receiving BoNT-B, reported mild to moderate flu-like symptoms [Baizabal-Carvallo 
et al, 2011]. 
In addition, although BoNT probably does not cross the blood–brain barrier [Truong et al, 2009], 
Hristova et al reported three cases of encephalitic clinical features that occurred shortly after treatment 
of focal dystonia with BoNT-A [Hristova et al, 2012].  
It must be highlighted that any potential differences in toxin spread characteristics among the different 
BoNT would be clinically relevant.  
Differences in the potential for contiguous spread among the BoNT products have been studied, but 
at the moment there is no clear evidence that differentiates the various products. It has been 
hypothesized that diffusion of neurotoxin into adjacent tissue is slower with the high molecular 
weight complex compared with the lower molecular weight or free neurotoxin [Dressler et al, 2012]. 
Therefore, theoretically, ONA with the highest complex size of 900 kD should be less diffusible, 
whereas INCO containing only the 150-kD neurotoxin (without NAPs) should be the most diffusible, 
with a higher rate of side effects related to toxin spread. However, this has not been demonstrated.  
On the other hand, progenitor toxin size may be irrelevant with regard to toxin diffusion, because all 
BoNT progenitor complexes immediately dissociate following injection [Wagman and Bateman, 
1953]; in addition, dissociation probably occurs in the vial on reconstitution with normal saline 
[Eisele et al, 2011]. This is consistent with data from an animal model, in which there were no 
significant differences in the field of effect among ABO, INCO, and ONA [Carli et al, 2009].  
However, several factors other than the pharmaceutical preparation such as dose, dilution, injection 
technique, target site, location of injection within the muscle, level of muscle hyperactivity, depth of 
injection, and post-injection rehabilitation could influence the potential for spread [Roche et al, 2008; 
Pickett, 2009; Brodsky et al 2012; Baricich et al, 2015].  
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BoNT-A doses, spread and adverse events in Post stroke spasticity treatment 
 
As reported above, in case of focal post stroke spasticity, BoNT-A injection is the gold standard 
therapy, with low prevalence of complications, reversibility, and efficacy in reducing spastic 
hypertonia [Simpson et al, 2016], with the approval of the U.S. Food and Drug Administration and 
the European regulatory agencies for this indication.  
Current guidelines suggest the employment of a dose up to 600 units (U) of onabotulinumtoxinA 
(Botox®, Allergan, Inc., United States) and incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals 
GmbH, Germany) or up to 1500 U of abobotulinumtoxinA (Dysport®, Ipsen, France) per injection 
session to treat spasticity after stroke [Wissel et al, 2009]. However, in recent years, higher doses 
were used, especially in case of upper and lower limb severe spasticity. It is known that low doses of 
BoNT-A can be used to increase motor function in those patients affect by spasticity graded 1 or 2 as 
measured by Modified Ashworth Scale (MAS) [Bohannon and Smith, 1987], whereas in the case of 
severe spasticity elevated doses of BONT-A may be useful to improve limb posture, to apply 
splinting, to consent hygiene, to increase passive articular range of motion, to walk and stand in 
patients with spastic equino-varus foot deformities, to improve joint range of motion and muscle 
extensibility or to reduce spasticity-related pain [Aoki, 2005]. However, many clinicians suggested 
that higher doses of BoNT-A may cause generalized, adverse effects [Hesse et al, 1995; Mancini et 
al, 2005; Varghese-Kroll and Elovic, 2009; Crowner et al, 2010; Thomas and Simpson, 2012]. In 
particular, Lange and colleagues (1987) hypothesized a possible relationship between BoNT-A dose 
and systemic effects, even if a clear relationship between dose and severity of symptoms was 
observed.  
In light of these considerations, the assessment of patients treated with high doses of BoNT-A should 
include a systematic evaluation of the presence of undesired, adverse events. Moreover, in association 
with clinical assessment, a non-invasive, instrumental evaluation should be considered to detect also 
subclinical diffusion of BoNT-A, in order to better undestand the pathophysiological mechanisms 
possibly involved in systemic side effects.  
 
Clinical assessment 
Hesse and colleagues [1995] published one of the first studies focused on high doses of BoNT-A. All 
patients of the group treated with 2000 U of AbobotulinumtoxinA (n=5) completed the study. Four 
weeks after injection they reported a muscle tone reduction, improved gait velocity, stride length, 
stance- and swing-symmetry without adverse effects, whereas a patient of the other group (treated 
with 1500 U) developed a bladder paresis, requiring catheterization for 14 days. 
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In a randomised, double-blind, dose-ranging study, Mancini and colleagues [2005] treated 45 patients 
with three different doses of OnabotulinumtoxinA, on the basis of suggestions in the literature. All 
the groups showed significant improvements after treatment. Group II (mean BoNT-A total dose: 322 
U) and Group III (mean dose: 540 U) showed a greater and more prolonged response than Group I 
(mean dose: 167 U). However, Group III showed the highest rate of adverse effects 4 weeks post-
treatment (prolonged weakness of the treated limb, flu-like syndrome and oedema of the injected leg).  
Varghese-Kroll and Elovic (2009) reported the first known case of repeated, contralateral weakness 
and fatigue after high-dose BoNT-A injection. A 53-yr-old woman developed contralateral weakness 
and fatigue, without autonomic symptoms, 2 weeks after receiving an injection with 800 units of 
onabotulinumtoxinA for management of poststroke spasticity. The patient reported resolution 4 
weeks later. The patient experienced the same, contralateral symptoms more than a year later, after a 
500 U injection, which took a similar length of time to resolve. Interestingly, three previous injections 
of onabotulinumtoxinA of 700 U, 500 U, and 600 U that were spaced three months apart were well 
tolerated.  
In a case series, Crowner and colleagues (2010) described the adverse effect (difficulty getting on/off 
his bus) of a 16-year old male treated with 640 U of onabotulinumtoxinA into the left flexor carpi 
radialis, flexor carpi ulnaris, pronator teres, flexor digitorum superficialis, biceps, brachioradialis, 
and quadriceps muscles. These symptoms lasted only one month. Interestingly, also in this study the 
Authors reported a previous, well tolerated injection of 635–640 U of BoNT-A. After a re-injection 
of 650 U of onabotulinumtoxinA into the same muscles, the patient presented weakness in both upper 
and lower extremities, dysarthria, and increased falls and gait instability after the injection. Twelve 
weeks post-injection, he had continued difficulty ascending stairs but was no longer falling and had 
regained full strength in his upper extremities.  
Thomas and Simpson also described [2012] contralateral weakness following repetitive 
onabotulinumtoxinA administrations in two patients affected by post-stroke spasticity.  
In the first case report, a 43-year-old woman, treated for more than one year with 575–700 U of 
OnabotulinumtoxinA into the upper and lower limb muscles without adverse effects, developed after 
a re-injection of 700 U total dose, contralateral weakness in the shoulder girdle and distal arm; 
generalized weakness, bulbar, respiratory, sphincter, pain, sensory symptoms, or other systemic 
symptoms were not reported.  
In the second case report, a 21-year-old woman with post-stroke spasticity and dystonia did not report 
adverse effects with total doses ranging from 550 to 700 U of onabotulinumtoxinA into the proximal 
upper limb muscles. However, after a new treatment in the same muscles with a total dose of 700 U, 
she reported weakness of her non-treated right arm, starting within days after the last injection. She 
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did not report neck pain, radiating symptoms to the right upper extremity, sensory disturbances, 
diplopia, dysphagia, or shortness of breath. The same symptoms were reported after the injection of 
600 U. However, no adverse effects were described with 500 U of onabotulinumtoxinA, avoiding 
any muscles proximal to the elbow. In this case, the Authors hypothesized the development of 
contralateral limb weakness for diffusion of BoNT-A through tissue planes from proximal upper 
extremity muscles, across the midline, to contralateral muscles.  
 
On the other hand, in recent years, many experienced clinicians investigated the effects of higher 
BoNT-A doses. In fact, as evidenced in expert consensus panel reviews [Wissel et al, 2009; 
Santamato et al, 2015] the recommended doses of BoNT-A in the product label reflect older clinical 
trials, whereas the clinical management of the patients could require higher doses in order to improve 
patients’ clinical outcome and quality of life [Picelli A, Baricich A et al, 2017]. Interestingly, in a 
recent survey, Bensmail and colleagues [2014] estimated that 24.6% of the patients could benefit 
from higher doses than those permitted by current country directives.  
 
In a prospective, non-randomized, open-label study, Santamato and colleagues [2013] described the 
safety and efficacy of higher doses (ranged from 750 to 840 U) of incobotulinumtoxinA in 25 subjects 
with upper and lower limb spasticity after stroke. The patients were treated under ultrasound guide in 
several muscles of the upper and lower limbs, reporting after 30 days of follow-up, a substantial 
improvement in functional disability, spasticity-related pain, and muscle tone. Only 16% of patients 
experienced treatment-emergent, mild adverse events (injection site pain, muscular weakness), 
resolved in a few days.  
Intiso and colleagues [2014] reported the effectiveness of high doses (up to 840 U) of 
incobotulinumtoxinA to treat spasticity due to brain injury or cerebral palsy. A significant reduction 
of muscle hypertone and pain was observed, but global functionality and arm dexterity were 
unchanged. Three patients (13.6%) complained of adverse events: of these, 2 subjects had local side 
effects consisting of injection site hematoma and one subject complained of weakness and reduction 
of active motility of the injected arm lasting for 2 weeks. No generalized side effects were observed.  
Dressler and colleagues [2015] demonstrated that high doses of incobotulinumtoxinA (minimum 400 
U and maximum 1200 U), injected into fifty-four patients suffering from spasticity of several 
etiologies, did not cause any generalized effects which could be attributed to BoNT therapy or 
complete secondary therapy failure. The Authors concluded that generalised weakness, being 
bedridden, feeling of residual urine and constipation were caused by the underlying tetra- or 
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paraparesis, blurred vision by presbyopia. Neurologic examination, serum chemistry and full blood 
count did not indicate any systemic adverse effects.  
In a retrospective analysis [Baricich et al, 2015], we evaluated the efficacy and safety of high doses 
of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb 
post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a 
significant muscle tone reduction and a significant functional improvement. No adverse events were 
reported.  
In a recent study, Wissel and colleagues [2017] evaluated safety (primary objective) and efficacy of 
increasing doses (400 U up to 800 U) of incobotulinumtoxinA for patients with limb spasticity. In 
this prospective, single-arm, dose-titration study, patients (18-80 years) with spasticity due to cerebral 
causes, who were clinically deemed to require total doses of 800 U incobotulinumtoxinA, received 3 
consecutive injection cycles with 400 U, 600 U, and 800 U incobotulinumtoxinA, respectively, each 
followed by 12-16 weeks' observation. In total, 155 patients were enrolled. IncobotulinumtoxinA 
dose escalation did not lead to an increased incidence of treatment-related AEs. No treatment-related 
serious AEs occurred. The Authors concluded that escalating incobotulinumtoxinA doses (400 U up 
to 800 U) did not compromise safety or tolerability, enabling treatment in a greater number of 
muscles/spasticity patterns with increased treatment efficacy.  
However, the available evidence mainly referred to a single set of injections evaluating the efficacy 
and safety of BoNT-A. Interestingly, in a recent prospective, non-randomized, open-label study, 
Santamato and colleagues [2017] studied the safety of repeated higher doses of incobotulinumtoxinA 
in post-stroke upper and lower limb spasticity. Two years after the first set of injections, they 
evaluated in 20 stroke survivors with upper and lower limb spasticity the long-term safety of repeated 
high doses of incobotulinumtoxinA (up to 840 U) for a total of eight sets of injections. In a two-year 
follow-up, repeated high doses of incobotulinumtoxinA, administered for eight sets of injections, 
appeared to be safe in patients with upper and lower limb spasticity after stroke without general 
adverse effects. 
 
 
Instrumental assessment  
As previously stated, the clinical manifestations of the systemic spread of BoNT-A, or remote effects, 
can be detected in various forms [Castaneda-Ramirez et al, 2013].  
 
In the past years, several studies analyzed the subclinical impairment of endplate function in non-
injected muscles by the use of neurophysiologic studies. 
Jitter measurements have been suggested as instrumental assessment to demonstrate abnormal 
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neuromuscular transmission in muscles remote from the site of BoNT injections [Sanders, 2002].  
A double-blind, placebo- controlled study of SFEMG changes in 42 patients assessed the efficacy of 
BoNT injections for cervical dystonia [Lange et al, 1991]. SFEMG was performed in a limb muscle 
before treatment and 2 weeks and 12 weeks after the injection of placebo or BoNT. Before and after 
treatment, the mean jitter was unchanged in the placebo group, whereas the mean jitter had a maximal 
increase after two weeks of BoNTA treatment and was still elevated after 12 weeks. The fiber density 
did not change in any patient during the study, and there were no remote clinical effects of BoNT.  
Girlanda and colleagues [1992] evaluated the distal effects of BoNT on neuromuscular transmission 
and on autonomic function in five patients who received BoNT-A injections for craniocervical 
dystonia and hemifacial spasm. Detection of increased neuromuscular jitter by single-fiber 
electromyography (SFEMG) on the extensor digitorum communis muscle and six tests of 
cardiovascular reflexes were performed The Authors reported that BoNT-A injections induced an 
increase in mean jitter value above normal limits in all patients as well as an increase of fiber density 
recorded six weeks after the treatment. However, the Authors conducted this study with BoNT-A 
Oculinum, which is significantly different from ONA [Borodic et al, 1996].   
Garner and colleagues [1993] analyzed repeated SFEMG in the extensor digitorum brevis muscle of 
eight patients who received a small dose of BoNT-A as therapy for focal dystonias in the head/neck 
region. They observed an increase of jitter and blocking in six of those patients. Fiber density of the 
extensor digitorum communis muscle on alternating sides showed a tendency to increase after BoNT-
A injection [Garner et al 1993] 
 
In addition to SFEMG, quantitative electromyography (EMG) has been described as a measure for 
distant effects of BoNT. A group of 27 patients with cervical dystonia was followed over an average 
of 31 months [Erdal et al, 1999]. They received repeated, unilateral BoNT-A injections of the 
sternocleidomastoid muscle (SCM), and quantitative EMG at rest and at maximal contraction were 
recorded. The study demonstrated no cumulative chemodenervation by repeated BoNT injections of 
the SCM measured by quantitative EMG. However, the contralateral, non-injected SCM showed 
significant reduction of quantitative EMG parameters, suggesting a functional weakening after long-
term treatment.  
 
Interestingly, since a frequent target of BoNT-A during botulism is the autonomic nervous system 
[Vita et al, 1987], several researchers have investigated autonomic function in patients with cervical 
dystonia receiving BoNT-A and BoNT- B, showing controversial evidence about the development of 
signs of subclinical diffusion.  
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In particular, heart rate variability (HRV), a simple and non-invasive electrocardiographic (ECG) 
derived measure, can provide detailed information about the control exerted by the autonomic 
nervous system (ANS) on cardiovascular activities including vagal and sympathetic components 
[Akselrod et al, 1981; Pomeranz et al, 1985; Kleiger et al, 1991; Tsuji et al, 1996; EuroAmerican 
Task Force, 1996]. Interest in these measures has recently increased in the light of predictive 
associations between reduced HRV and increased mortality after an acute myocardial infarction and 
between HRV and the incidence of coronary heart disease [Wichterle et al, 2004]. HRV has been 
categorised into high frequency (HF), low frequency (LF) and very low frequency (VLF) power 
ranges according to its frequency. HF is equivalent to the well-known respiratory sinus arrhythmia 
and is considered to represent vagal control of heart rate. LF is jointly contributed by both vagal and 
sympathetic nerves  [Wichterle et al, 2004]. Because of its accessibility and non-invasiveness, 
frequency domain analysis of HRV has gained its popularity with broad clinical and research 
applications as a functional indicator of the ANS activity.  
In previously published literature, there are few works investigating HRV modifications after BoNT-
A injection, with contrasting results. 
In a previously cited study, Girlanda et al [1992] observed in patients affected by cervical dystonia 
and hemifacial spasm significant differences in autonomic cardiac drive. As  descrived above, this 
study was mainly an EMG study, conducted with BoNT-A Oculinum, which is significantly different 
from onabotulinumtoxinA [Borodic et al, 1996], and methods used to monitor the autonomic effects 
at cardiac level are not clearly described.  
Nebe and colleagues [1996] showed that abobotulinumtoxinA did not modify significantly HRV in 
patients treated for cervical dystonia. 
Meichsner et al [2005] evaluated the effect of BoNT-A on HRV in a quite large sample of patients 
affected by different diseases (cervical dystonia, spasticity and hyperhidrosis). They showed a 
reduction in the very low frequency domain and in the high frequencies in those treated with 
abobotulinumtoxin A, and a very marked reduction in the low frequencies in those treated with 
rimabotulinumtoxin B.  
A short-term power spectral analysis of heart rate and systolic blood pressure variability, high-
frequency and low-frequency oscillations of heart rate variability, low frequency/high frequency 
ratio, and baroreflex sensitivity were measured in 12 patients with cervical dystonia before and 2 to 
4 weeks after onabotulinumtoxinA injection and were compared with normative data [Tiple et al, 
2008]. Their data demonstrated a dose-dependent effect on neuromuscular transmission in distal 
muscles, possibly owing to hematogenous spread of BoNT-A through the bloodstream. Overall, these 
results suggest that the effect of locally injected, intramuscular BoNT-A on autonomic cardiovascular 
 21 
innervation cumulates over time. None of these findings, however, were noticed by the patient, nor 
were they clinically relevant.  
However, it must be pointed out that in cervical dystonia doses are largely inferior to those utilized 
in spasticity.  
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Personal contributions  
 
In the last years, our research group deeply investigated the possible effect on autonomic nervous 
system of high doses of BoNT-A. 
In a case control study [Invernizzi et al, 2015], we evaluated the changes in autonomic heart drive 
induced by high doses (higher than 600 units) of IncobotulinumtoxinA injection in patients affected 
by post stroke spasticity. Moreover, we considered the treatment safety by monitoring adverse events. 
Each patient underwent an ECG recording before injection and 10 days after treatment. Linear and 
non-linear HRV measures were derived from ECGs with a dedicated software. None of the variable 
considered showed statistically significant changes after BoNT-A injection.  
More recently, in order to confirm these results, we evaluated changes in HRV induced by high doses 
(>600 U) of IncobotulinumtoxinA or OnabotulinumtoxinA [Baricich et al, 2017]. We recruited 
patients affected by post stroke spasticity in a single blind, randomized controlled crossover study. In 
the first part of the study, patients in the first group were injected with incobotulinumtoxinA while 
patients in the second group with onabotulinumtoxinA; after 6 months, a crossover intervention was 
performed. All patients were blinded to BoNT-A type, and performed an ECG registration in the 24 
h before injection (t0) and 10 days after treatment (t1), both in the first and in the second part of the 
study. Functional status was also evaluated. In this study HRV analysis showed no significant changes 
after each BoNT-A injection in both groups at any evaluation time. Moreover, no statistically 
significant differences were found regarding each variable between the two groups. 
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Abstract  
Background. The most important adverse effect of BoNT-A is the systemic diffusion of the toxin. 
There is some evidence that the administration of high doses can increase the risk of systemic 
diffusion and the development of clinically evident adverse effects, however an international 
consensus does not exist about its maximum dose.  
Aim. The aim of this study was to evaluate changes in autonomic heart drive induced by high doses 
(higher than 600 units) of incobotulinumtoxinA injection in spastic stroke patients. Moreover, the 
treatment safe- ty by monitoring adverse events occurrence was as- sessed.  
Design. Case control study. 	
Population. Eleven stroke survivors with spastic hemiplegia. 	
Methods. Patients were treated with intramuscular focal injections of IncobotulinumtoxinA (NT 201; 
Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany). Doses were below 12 units/Kg. Each 
patient underwent an ECG recording before injection and 10 days after treatment. Linear and non-
linear Heart Rate variability (HRV) measures were derived from ECGs with a dedicated software. 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Results. None of the variable considered showed statistically significant changes after BoNT-A 
injection.  
Conclusion. The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be 
safe regarding autonomic heart drive. 	
Clinical Rehabilitation Impact. The use of IncobotulinumtoxinA up to 600 units could be a safe 
therapeutic option in spastic hemiplegic stroke survivors.  
 
Key words: Botulinum toxins, Type A, Stroke; Muscle spasticity; Heart rate.  
 
 
Introduction  
Botulinum toxin type A (BoNT-A) has been utilized from more than twenty years to treat focal 
spasticity in different pathologies such as stroke, traumatic brain injury, cerebral palsy and multiple 
sclerosis. In Europe and in the USA BoNT-A is available with three established drug names: 
abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA. Even if these three products 
are not interchangeable, the suggested dose ratio is 1:1 for ona- and incobotulinumtoxinA,1-3 while 
for the conversion ratio between ona- and incobotulinumtoxinA or abobotulinumtoxinA the reported 
ratio ranges are from 1:3 4 to 1:4 5 or 1:5.6, 7 At present time, despite it has been clinically utilized 
for several years, a clear international consensus does not exist about recommended and maximum 
BoNT-A dose. Current guidelines suggest maximal doses ranging from 360 to 400 units of 
onabotulinumtoxinA and 1000 units of abobotulinumtoxinA.8 However, in some countries, the use 
of up to 600 units of onabotulinumtoxinA or incobotulinumtoxinA is admitted,9 and the safe 
administration of even higher doses of incobotulinumtoxinA in the adult patient if medically indicated 
is reported as well.10, 11  
BoNT-A has shown to be effective,12 safe 13 and well tolerated,14, 15 but some adverse effects can 
occur, and the most important is the local and systemic diffusion of the toxin.16 There is some 
evidence that the administration of higher doses can increase the risk of systemic diffusion and the 
development of clinically evident adverse effects 17 that can resemble, to a lesser extent, those seen 
during botulism. Since a frequent target of BoNT-A during botulism is the autonomic nervous 
system,18 several researchers have investigated autonomic function in patients with cervical dystonia 
receiving BoNT-A and BoNT- B, showing controversial evidence about the development of signs of 
subclinical diffusion.19-23 However, in cervical dystonia doses are largely inferior to those utilized 
in spasticity, and, to our knowledge, nobody at present time has investigated the possible effect on 
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autonomic nervous system of high doses of BoNT-A.  
Heart rate variability (HRV), a simple and non-invasive electrocardiographic (ECG) derived measure, 
can provide detailed information about the control exerted by the autonomic nervous system (ANS) 
on cardiovascular activities including vagal and sympathetic components.24-28 Interest in these 
measures has recently increased in the light of predictive associations between reduced HRV and 
increased mortality after an acute myocardial infarction and between HRV and the incidence of 
coronary heart disease.29 HRV has been categorized into high frequency (HF), low frequency (LF), 
and very low frequency (VLF) power ranges according to its frequency. HF is equivalent to the well-
known respiratory sinus arrhythmia and is considered to represent vagal control of heart rate. LF is 
jointly contributed by both vagal and sympathetic nerves.29 Because of its accessibility and non-
invasiveness, frequency domain analysis of HRV has gained its popularity with broad clinical and 
research applications as a functional indicator of the ANS activity.  
The aim of this study was to evaluate changes in HRV induced by high doses (higher than 600 units) 
of incobotulinumtoxinA injection in spastic stroke patients. Moreover, we assessed the treatment 
safety by monitoring adverse events occurrence.  
 
Matherials and methods 
We recruited 11 stroke survivors with spastic hemiplegia (5 male and 6 female) aged from 44 to 72 
years at the Rehabilitation Unit of the Maggiore Hospital in Novara. Demographic data are resumed 
in Table 1.  
The inclusion criteria were: 1) focal spasticity graded >= 2 on Modified Ashworth Scale at upper an 
lower limb muscles, requiring at least 600 incobotulinumtoxinA units; 2) hemiplegia after ischemic 
or hemorrhagic stroke documented by CT scan and/ or available case history; 3) age >18 years. 
Exclusion criteria were: 1) heart failure with NYHA>=3; 2) previous diagnosis of cardiac arrhythmia; 
3) concomitant use of beta-blockers; 4) pace-maker implant; 5) presence of fixed contractures at 
BoNT-A target muscles.  
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After enrollment patients were injected with IncobotulinumtoxinA (NT 201; Xeomin®, Merz 
Pharmaceuticals GmbH, Frankfurt, Germany) with a dilution of 100 units/2 mL of 0.9 % sterile 
saline). All patients received doses below 12 units/Kg. The study protocol consisted in two ECG 
recordings of 30 minutes each, the first one has been performed in the 24h before 
incobotulinumtoxinA injection (Baseline) and the second one 10 days after the treatment. Each ECG 
recording was performed in a quiet room with a constant temperature of 24° C with an analogical 
ECG recorder. Participants were instructed to avoid a heavy meal, to abstain from smoking, caffeine 
beverages and alcohol and to avoid physical activity for at least two hours prior to ECG measurement. 
All examinations were performed from 11 to 15 h to limit circadian influences on cardiac rhythm. 
Treatment safety was assessed by monitoring adverse events occurrence of any degree. Lastly, the 
following functional measures were recorded at baseline: Barthel Index,30 Motricity Index (MI) for 
upper and lower limb,31 Functional ambulation category (FAC).32  
Data obtained from analogic ECG were processed with an A/D converter (micro 1401 CED© 
Cambridge Electronic Design, Cambridge, UK) and recorded on a PC by means of a data acquisition 
system (Spike2 v.5, CED) with a sampling rate of 3000 Hz. Guidelines were followed for time 
recordings, sampling rate and HRV analysis of electrocardiograms.27 Artifacts and noise regions 
were removed and in case of premature beats they have been manually corrected. Only recordings 
that contained <1% of premature beats were considered.  
 
HRV outcome measures  
ECG’s have been analyzed by means of a software called “Kubios HRV analysis”, the evolution of 
the software “HRV analysis” originally created by Niskanen et al.,33 which can perform a wide range 
of measurements of HRV.  
HRV indexes can be classi ed in two main categories: linear and non-linear variables.34  
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Linear variables  
The so called time-domain variables simply calculate the intervals and standard deviations between 
each consecutive RR interval and are the easiest and simplest among all the HRV variables.  
1. The Standard Deviation of RR intervals (SDNN) reflects the overall (both short-term and long-
term) variation within the RR interval series, whereas the standard deviation of successive RR interval 
dif-ferences (SDSD), can be used as a measure of the short-term variability. These measurements of 
short- term variation estimate high frequency variations in heart rate and thus are highly correlated.  
2. Geometrical Indexes (TINN and RR tri-index) express overall HRV measured over 24 h and are 
more influenced by the lower than by the higher frequencies. The major disadvantage is the need for 
a reasonable number of NN intervals to construct the geometric pattern. In practice, recordings of at 
least 20 min (but preferably 24 h) should be used to ensure the correct performance of the geometric 
methods.27, 33  
The other category in this group are frequency-domain variables based on spectral analysis which 
provide direct information about the vagal and sympathetic activity driven to the heart. The power 
ranges commonly suggested by guidelines and used in this study are the following: very low 
frequency (VLF, <0.04 Hz), low frequency (LF, rang- ing from 0.04 to 0.15 Hz) and high frequency 
(HF, ranging from 0.15 to 0.4 Hz).27 Frequency Domain variables are rather complex compared to 
time do- main, however they are commonly and extensively used for both clinical (Holter recordings) 
and re- search purposes.27  
 
Non-linear Variables  
In the non-linear group are included variables based on complex mathematical fractal algorithms, 
which are able to investigate the deep correlations between ANS, Central nervous system, 
hemodynamic and cardiac electrophysiology.34 However, whereas these algorithms have been 
demonstrated as powerful tools in describing and predicting the behavior of complex systems in 
different science fields, at present time their use in large cohorts of patients has not been performed, 
so the evidence of their reliability in the medicine is scarce. Notwithstanding, since they are not 
affected by non-stationarity, as it happens for linear HRV indexes, they are a promising technique in 
light of the vision of physiological processes in the human body as the result of a complex interaction 
between multiple systems. Among these variables we used the one provided by the HRV software: 
the Poincaré plot, Approximate Entropy (ApEn), Sample Entropy (SampEn), the Detrended 
fluctuation analysis (DFA) with short term and long term fluctuation slope (α1 and α2), correlation 
dimension (D2), and lastly the recurrence plot (RP) with the following variables: mean line length 
(Lmean), Maximum line length (Lmax), recurrence rate (REC), determinism (DET) and Shannon 
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Entropy (ShanEn). A more detailed description is available in the Annex I.  
 
Statistical analysis  
Statistical analysis was performed using the GraphPad 4 package, version 4.0 (GraphPad Software, 
Inc., San Diego, CA, USA). Due to the small sample size we supposed a non-gaussian distribution of 
variables. Thus, differences between single-variable measurements in each group were evaluated with 
Wilcoxon’s signed-rank test. A type I error level of 0.05 was chosen. In order to obtain comparable 
and univocal data, for frequency domain variables only the power ranges expressed in normalized 
units were statistically analysed.27  
 
Results  
Demographic data of patients enrolled, mean doses of incobotulinumtoxinA used and injection sites 
are resumed in Table I. Details of injected muscles and single doses of incobotulinumtoxinA used for 
each patient are resumed in Table II. As shown in T able III and Table IV, none of the variable con- 
sidered for time, frequency domain and non linear domain showed statistically signi cant changes 
after BoNT-A injection. Moreover, none of the patients enrolled in the study experienced adverse 
event after injection.  
 
Discussion 
Our data show that high doses of incobotulinumtoxin A do not influence the autonomic drive directed 
to the heart in stroke survivors with spasticity. Moreover, no clinical adverse events of any kind 
occurred in anyone of our patients.  
The absence of relevant effect on autonomic drive directed to the heart may have a clinical relevance 
when deciding to treat with high doses of BoNT-A stroke survivors affected by cardiovascular 
comorbidities, in which it is known that a reduction in HRV is able to increase the incidence of 
cardiovascular events29.   
Moreover, even in patients without known cardiac diseases, our results can limit the potential 
concerns about the use of incobotulinumtoxinA at a dosage greater than 600 units. 17 Actually, dose 
limitations often influence the clinician’s decision about which muscles should be injected. There are 
few previous works investigating HRV modifications after BoNT-A injection with contrasting 
results. Wissel et al. showed that BoNT-A did not modify significantly HRV;21 however, this study 
was performed on patients with cervical dystonia treated with abobotulinumtoxin A at lower dosages 
than those utilized in our study. In a more recent paper, Tiple et al.23 showed mild, subclinical 
abnormalities in autonomic cardiovascular regulation after treatment with onabotulinumtoxin A in 
 29 
patients with cervical dystonia. However, this study was conducted with a different toxin and at doses 
far lower than in our study. Meichsner et al. 35 evaluated the effect of BoNT-A on HRV in a quite 
large sample of patients affected by different diseases (cervical dystonia, spasticity and 
hyperhidrosis). They showed a reduction in the very low frequency domain and in the high 
frequencies in those treated with abobotulinumtoxin A, and a very marked reduction in the low 
frequencies in those treated with rimabotulinumtoxin B. Again, it should be noted that the used doses 
were much lower than in our study. Lastly, Girlanda et al. 19 found in patients affected by cervical 
dystonia and hemifacial spasm significant differences in autonomic cardiac drive. This study was 
mainly an EMG study, con ducted with Oculinum, which is signi cantly different from 
onabotulinumtoxinA,36 and methods used to monitor the autonomic effects at cardiac level are not 
clearly described.  
These effects, even if inconsistent, can be explained by the diffusion of the toxin far from the injection 
side, via the blood circulation or via the retrograde transport and transcytosis to the central nervous 
system.37 These mechanisms could explain the reduction in vagal control of the heart,38 that has 
been observed also in botulism.18, 39, 40 It should be remembered that there are some evidence that, 
in both animals 41 and humans, 42, 43 BoNT-A can spread far from the injection site. However, the 
clinical relevance of these phenomena has never been clarified and they probably remain observations 
without consequences for patients.  
 
Conclusions  
In conclusion, our work, even if it has been carried out on a relatively small sample, confirms that the 
use of incobotulinumtoxin A in adult patients at doses up to 12 units/kg seems to be safe regarding 
autonomic heart drive.  
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Abstract  
We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 
to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were 
assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and 
a significant functional improvement (assessed with the Disability Assessment Scale). No adverse 
events were reported. In our retro- spective analysis the treatment with high doses of 
onabotulinumtoxinA showed to be effective and safe.  
Keywords: Stroke Spasticity Botulinum toxin type A OnabotulinumtoxinA Higher doses  
 
Introduction  
Post-stroke spasticity (PSS) has been described as a relevant clinical problem in stroke survivors, as 
it can impair manual dexterity, mobility and balance, with a negative impact on independence (Martin 
et al. 2014).  
OnabotulinumtoxinA has been proposed as a part of effective integrated treatment programme for the 
management of PSS (Brashear et al. 2002a, b; Wissel et al. 2009; Baker and Pereira 2013).  
Clinical experience showed a good safety profile (Ghasemi et al. 2013) both in the short- (Naumann 
and Jankovic 2004) and in the long-term use (Naumann et al. 2006).  
The optimal dose for onabotulinumtoxinA is deter- mined by the patient’s characteristics and by the 
treatment’s goal but there is not a general consensus on maximum dose. Francisco (2004) suggested 
a dose up to 400–600 units (U) per session, whereas Wissel et al. (2009) remarked that it should not 
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exceed 600 U. However, in clinical practice doses as high as 800 U are used by some practitioners, 
even if safety and efficacy of routine use of doses higher than 500 U still await further evidence 
(Francisco 2004).  
The aim of our study was to retrospectively evaluate the efficacy and safety profile of higher doses 
of onabotulinumtoxinA (up to 800 U) in patients affected by upper and/or lower limb PSS.  
 
Materials and methods  
Patients  
We retrospectively analysed data from 119 patients affected by upper and/or lower limb PSS who 
referred to the Physical and Rehabilitative Medicine Unit of University Hospital ‘‘Maggiore della 
Carita`’’ in Novara (Italy) between July 2012 and April 2014.  
The inclusion criteria were: spasticity due to an ischemic or hemorrhagic stroke; time from stroke at 
least 6 months; total dose required of onabotulinumtoxinA >=600 U; age >18 years. The exclusion 
criteria were: previous treatment with Botulinum Toxin Type A (BoNT-A) in the last 4 months; 
spasticity due to any other cause; presence of other concomitant neurological or neuromuscular 
diseases; dementia; concomitant therapy with myorelaxants (oral or intrathecal baclofen, 
benzodiazepines, tizanidine); previous treatment of PSS with phenol, alcohol injection or local 
surgery; presence of fixed contractures or muscular fibrosis at ultrasound evaluation that could have 
negatively influenced the treatment with onabotulinumtoxinA.  
26 patients who fulfilled the inclusion criteria were included in this study; 93 patients were excluded 
due to treatment with other BoNT-A formulations (abobotulinumtoxinA, incobotulinumtoxinA) or 
doses of onabotulinumtoxinA \600 U.  
Each patient and/or caregiver gave his/her written consent before the treatment.  
Assessment  
The same physician evaluated all the patients before treatment and 1 and 3 months after injections, 
as performed in clinical routine. Before treatment the patients, together with the treating physician, 
chose their primary therapeutic target between the four domains of the Disability Assessment Scale 
(DAS), i.e. dressing, limb position, pain and hygiene (Brashear et al. 2002a, b). At baseline and 30 
and 90 days after treatment the functional impairment of the upper limb was evaluated with DAS (a 
four-point scale from 0 = no disability to 3 = severe disability), whereas changes in muscle tone were 
assessed with Modified Ashworth Scale (MAS) (a five-point scale from 0 = no increase in tone, to 4 
= affected parts rigid in flexion or extension) (Brashear et al. 2002a, b; Bohannon and Smith 1987).  
To evaluate the efficacy of the treatment, investigators, patients and their caregivers were asked to 
rate the patients’ overall treatment tolerability (Global Assessment of Effi- cacy, GAE) in a four-
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point scale (from 1 = very good to 4 = poor) after a postinjection period of 30 and 90 days (Kanovsky 
et al. 2011).  
In addition, a clinical examination was performed to evaluate the safety of the treatment and the 
presence of adverse events, which were assessed at each visit using a semi-quantitative scale (0, no 
adverse effects; 4, serious adverse effects) (Mancini et al. 2005).  
Treatment  
OnabotulinumtoxinA (Botox®, Allergan Inc., Irvine CA) was administered in 2 mL of 0.9 % dilution 
saline; the injections were performed under ultrasonographic guide by the same investigator. The 
clinicians planned target muscles, doses and number of injection sites for each muscle depending on 
spastic hypertonia grade and muscle size. After onabotulinumtoxinA injection, all patients 
participated in a 10 day-rehabilitation programme (electrical stimulation and stretching of injected 
muscles, strengthening exercise, gait training if applicable).  
Statistical analysis  
Since data were not normally distributed, according to Shapiro–Wilk test (data not shown), within-
group comparisons were made using the Friedman test for repeated measures. In addition, Dunn’s 
Multiple Comparison Test was performed to evaluate differences between single variable 
measurements (t1 vs t0, t2 vs t0 and t2 vs t1).  
For statistical purpose, a MAS score ‘‘1’’ was considered as 1, a MAS score ‘‘1+’’ as 2, and so on 
until 5 (Biering- Sørensen et al. 2006). An alpha error level of 0.05 was chosen.  
Statistical analysis was performed using GraphPad Prism 1.4 for Macintosh OS 10.6.  
 
Results  
The demographical and clinical characteristics of the 26 patients studied are represented in Table 1. 
Considering all the patients, 23 of them received the treatment at both upper and lower limb, whereas 
3 patients were treated at lower limb only. 14 patients (53.8 %) were naive to treatment with 
onabotulinumtoxinA (8 previously treated with other BoNT-A formulations, 6 naive to any BoNT-A 
formulation for spasticity).  
Muscles treated and relative doses are shown in Table 1.  
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Concerning the GAE, both 30 days (t1) and 90 days (t2) after injection patients, caregivers and 
clinicians rated the efficacy of treatment as ‘‘good’’ or ‘‘very good’’, except in one case where it was 
evaluated as ‘‘moderate’’ by clinicians. The complete results of GAE are represented in Table 2, 
together with the results of clinical evaluations with MAS and the principal target in DAS at baseline 
(t0), t1 and t2.  
Spasticity after injections showed a significant reduction (p <0.0001) considering MAS results at 
elbow/shoulder, wrist/finger, thigh and leg. We observed a significant reduction in muscle tone in all 
muscle groups both at t1 vs t0 and t2 vs t0, whereas no significant difference was seen at t2 vs t1 
(Table 2). As primary therapeutic target in DAS evaluation, 18 patients (69.2 %) chose limb position, 
4 patients (15.4 %) dressing, 3 patients (11.5 %) hygiene and 1 patient (3.9 %) chose pain. Notably, 
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a significant improvement in DAS principal target score has been observed at t1 vs t0 (p\0.001) and 
t2 vs t0 (p\0.05).  
No adverse events were reported in patients’ group (mean score 0).  
 
 
 
Discussion  
In our study, we observed a significant muscle tone reduction and clinical improvement with high 
doses of onabotulinumtoxinA, without any adverse events.  
In recently published literature, the efficacy and safety of higher doses of incobotulinumtoxinA in 
PSS treatment has been described: Santamato et al. (2013) reported no adverse events in 25 patients 
with upper and lower limb PSS, evaluated 30 and 90 days after injections with doses up to 840 U; 
moreover, Invernizzi et al. (2014) evaluated changes in autonomic heart drive potentially induced by 
doses greater than 600 U, without meaningful alterations in linear and non linear Heart Rate 
Variability measures in 11 stroke survivors.  
On the other hand, the current recommended dose of onabotulinumtoxinA is 400 U per session (Brin 
1997) and, even if clinical experience suggests a maximum dose of 600 U (Francisco 2004; Wissel 
et al. 2009), there is no evidence of safety for doses greater than 500 U except for paediatric patients 
(Francisco 2004; Goldstein 2006).  
Interestingly, Mancini et al. (2005) reported minor adverse effects (generalised weakness, weakness 
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of the treated limb, flu-like syndrome and oedema; mean score 1.2) 4 weeks after administration of 
onabotulinumtoxinA in lower limb PSS, with a mean dose of 540 U. In addition, also Varghese-Kroll 
and Elovic (2009) presented a case report about contralateral weakness and fatigue after re- peated 
high doses (800 and 500 U) of onabotulinumtoxinA for PSS.  
In our study, the mean total dose of onabotulinumtoxinA was 676.9 ± 86.3 U, but we did not report 
any adverse event. A possible explanation might be the use of ultra- sonography to identify target 
muscles; in fact, as reported by Henzel et al. (2010), ultrasound localization may improve accuracy 
of needle placement, avoiding injection into vascular structures and reducing the potential risk of 
systemic diffusion of BoNT-A. Moreover, this technique can improve clinical outcome both in upper 
and lower limb PSS (Picelli et al. 2014; Santamato et al. 2014).  
To our knowledge, this is the first study showing the safety and the efficacy of PSS treatment with 
doses of onabotulinumtoxinA up to 800 U, higher than those typically used in clinical practice for 
PSS.  
Nevertheless, we have to take into account that our paper suffers for the limitations of a retrospective 
study, as selection bias and observer bias. Besides that, the sample size is relatively small.  
Further research is required to better identify the optimal dose of onabotulinumtoxinA to optimize 
clinical outcome and safety profile.  
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Dear Sir,  
Stroke is a major cause of long-term disability. Post-stroke spasticity (PSS) has been described as a 
velocity-dependent increase in muscle tone with exaggerated tendon jerks, resulting from 
hyperexcitability of the stretch reflex and presenting as intermittent/sustained involuntary muscle 
activation (Pandyan et al., 2005). In clinical practice, accurate quantitative measures of spasticity can 
be difficult to obtain in a single examination: indeed, PSS can be modified in different conditions, 
e.g. static conditions as opposed to dynamic situations, such as walking. In addition, the impact of 
PSS on subjective sensations and activities of daily living (ADL) can be hard to describe. 
Furthermore, in order to optimize treatment procedures in patients with PSS, assessment of patient-
reported outcomes and perceptions should be reported, given that sensorimotor alterations due to PSS 
may influence “interoception”, i.e. the sense of the physiological condition of the entire body (Craig, 
2002; Franceschini et al., 2014).  
In order to improve understanding of these components of PSS, we studied 116 adults affected by 
first-ever unilateral stroke (more than 3 months from onset) with spasticity (less than 3 months from 
the last botulinum toxin treatment) in the affected arm (41 right hemiparesis and 75 left hemiparesis), 
graded ≥1 on the Modified Ashworth Scale (MAS). Spasticity was measured with the MAS in the 
affected shoulder, elbow, wrist and fingers, and associated reactions of the affected arm were 
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recorded during the sit-to-stand movement and during walking. Also the following variables were 
evaluated in the affected arm: Motricity Index (MI) sub-items for the upper limb; active range of 
motion of the shoulder, elbow, wrist and finger (percentage differences from normal values); self-
assessment of functioning of the arm during ADL, as rated on a visual analog scale (0 no use; 100 
normal use); Disability Assessment Scale; and self-estimation of pain, heaviness and rigidity in the 
shoulder, elbow, wrist and finger joints according to the Numerical Rating Scale (NRS) (0 no 
symptom; 100 worst symptom). Afterwards, we performed a principal component analysis (PCA), 
which is a variable reduction procedure, in order to obtain a smaller number of principal components 
(artificial variables), and also because the PCA would account for the variance in the observed data, 
while retaining most of the information from the sample.  
On the basis of the PCA results, we defined three classes based on the main unpleasant sensations 
reported by each patient (heaviness, rigidity and pain) as follows: Class I (29 patients; 12 right 
hemiparesis and 17 left hemiparesis; mean age 63.4 years; mean time from stroke onset 58.2 months) 
corresponded to a higher level of proximal (shoulder) heaviness and a low level of pain (NRS 23.3 
and 12.7, respectively); Class II (29 patients; 11 right hemiparesis and 18 left hemiparesis; mean age 
60.7 years; mean time from stroke onset 74.1 months) corresponded to the highest level of rigidity 
(NRS 59.5, 70.7, 77.8 and 76.4 at the shoulder, elbow, wrist and fingers, respectively) and pain (NRS 
17.1, 7.9, 11.7 and 13.1 at the shoulder, elbow, wrist and fingers, respectively); Class III (58 patients; 
18 right hemiparesis and 40 left hemiparesis; mean age 63.2 years; mean time from stroke onset 70.9 
months) corresponded to a lower level of heaviness (NRS 12.8, 2.7, 1.3 and 1.1 at the shoulder, elbow, 
wrist and fingers, respectively), the intermediate level of rigidity (NRS 21.5, 27.8, 21 and 18.1 at the 
shoulder, elbow, wrist and fingers, respectively), a greater level of functional ability and a low level 
of proximal (shoulder) pain (NRS 13.3).  
According to the non-parametric Kruskal-Wallis test (alpha level for significance p<0.05), no 
significant differences were found between Classes I, II and III in the MAS (shoulder adductors, 
elbow flexors, wrist and finger flexors) and MI (shoulder, elbow and pinch grip) scores. On the basis 
of this finding, we suggest that unpleasant sensations of pain, heaviness and rigidity may relate not 
only to muscle tone (as measured by the MAS), but also to altered proprioceptive and body ownership 
information, as well as to the individual’s self-estimated ability to achieve functional goals. This is 
in keeping with previous findings about the impact of PSS on limitations in ADL, wellbeing and life 
satisfaction, which may not be indicated by quantitative scores but are demonstrated by patient-
reported outcome measures (Sunnerhagen and Francisco, 2013). Indeed, PSS also has an afferent, 
sensory component, which might be related to some differences in the sensations described by 
patients (Craig, 2002; Franceschini et al., 2014). It is well known that proprioceptive afferent 
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information coming from mechanoreceptors in joints, muscles, tendons and stretch-sensitive 
receptors in the skin, together with efferent motor signals, can play a key role in postural schema 
understood as dynamic representations of body posture. Moreover, the sense of body ownership, too, 
is presumably developed using sensory information, as recently described by Walsh and colleagues 
(2011), who demonstrated that non-tactile proprioceptive cues might contribute to this sense. 
Another possible explanation for the current observations could be related to problems occurring in 
patient-provider communication and the role that this communication plays in PSS rehabilitation 
within the context of patient-centered health care, which addresses illness from a holistic perspective 
(Sunnerhagen and Francisco, 2013). Furthermore, treatment goals should be patient-centered and the 
rehabilitation program should be tailored to the needs of each patient, identifying what they describe 
as limitations and trying to focus on possible correlations between these and PSS.  
In conclusion, our patients with PSS described different patterns of sensations even without showing 
significant differences in their MAS and MI scores. We suggest that PSS might be considered not 
only as a modification of muscle tone, but also as a clinical condition that is specific to the single 
patient, and has a significant impact on his/her sensations and self-estimated autonomy in ADL. 
Future studies are needed to further investigate these issues.  
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Abstract 
Background: Botulinum toxin type A is a valid and safe treatment for focal spasticity, with 
documented effects on both sympathetic and parasympathetic systems. Heart rate variability can 
provide detailed information about the control of the autonomic nervous system on cardiovascular 
activities. Previous studies in literature showed no significant changes in Heart Rate Variability with 
doses >600 U of incobotulinumtoxinA in chronic post stroke spastic patients; however, at present 
time, these results have not been confirmed with doses >600 U of onabotulinumtoxinA.  
Aim: To evaluate changes in Heart Rate Variability induced by high doses (>600 U) of 
incobotulinumtoxinA or onabotulinumtoxinA in spastic stroke patients over a 1-year period. 	
Design: single blind randomized controlled crossover study design. 	
Setting: Rehabilitation Unit of the University Hospital in Novara.  
Population: 10 stroke survivors with spastic hemiplegia (Modified Ashworth Scale >=2) were 
recruited and randomly divided in two groups (A and B). 	
Methods: In the first part of the study, patients in Group A were injected with incobotulinumtoxinA 
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while patients in Group B with onabotulinumtoxinA; after 6 months, a crossover intervention was 
performed. All patients were blinded to Botulinum toxin type A type, and performed an ECG 
registration in the 24 h before injection (t0) and 10 days after treatment (t1), both in the first and in 
the second part of the study. Functional status was evaluated with Barthel Index, Motricity Index and 
Functional Ambulation Category scores.  
Results: Heart Rate Variability analysis showed no significant changes after each Botulinum toxin 
type A injection in both groups at any evaluation time. Moreover, no statistically significant 
differences were found regarding each variable between the two groups. 	
Conclusions: Our data show that high doses (>600 U) of incobotulinumtoxinA and 
onabotulinumtoxinA do not influence the cardiovascular activity of the autonomic nervous system in 
chronic hemiplegic spastic stroke survivors.  
 
 
 
1. Introduction 
Botulinum toxin type A (BoNT-A) has been considered as an effective and safe treatment for focal 
spasticity in stroke survivors (Baker and Pereira, 2013). BoNT-A can directly modify the heart 
function acting on the sympathetic (through the preganglionic sympathetic innervation) and 
parasympathetic systems (through the vagal nerve) (Girlanda et al., 1992), and at present time there 
is no general consensus on the maximum dose of BoNT-A in terms of safety and clinical 
interchangeability among the three commercially approved products (abobotulinumtoxinA, 
onabotulinumtoxinA, incobotulinumtoxinA). In clinical practice the maximum dose admitted per 
session is up to 400-600 units (U) both for onabotulinumtoxinA (Francisco, 2004; Brin, 1997) and 
for incobotulinumtoxinA (Wissel and Kempf, 2012). However, two recent open-label studies 
suggested the safety of doses up to 840 U of incobotulinumtoxinA (Santamato et al., 2013) and of 
doses up to 800 U of onabotulinumtoxinA (Baricich et al., 2015) for spasticity treatment in stroke 
survivors.  
Heart Rate Variability (HRV) is a simple and non-invasive electrocardiographic derived measure 
useful to monitor the control of the autonomic nervous system (ANS) on cardiovascular activities 
including vagal and sympathetic ones (Task Force, 1996; Akselrod et al., 1981). In consideration of 
its accessibility and low invasiveness, HRV measurement represents a functional indicator of the 
ANS activity, being a valid method to study the potential impact of high doses of BoNT-A on the 
autonomic drive directed to the heart in stroke survivors.  
Recently no relevant changes have been showed in the autonomic heart drive measured by HRV with 
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doses >600 U of incobotulinumtoxinA in patients with chronic spasticity (Invernizzi et al., 2015). 
However, at present time, instrumental data about safety of high doses (>600 U) of 
onabotulinumtoxinA in chronic stroke survivors are lacking. To our knowledge, only Dressler 
evaluated in a crossover study the safety of high doses of incobotulinumtoxinA (mean dose 450.5 ± 
177.1 U) in patients affected by spasticity and previously treated with onabotulinumtoxinA at same 
doses, showing no differences between the two products in terms of efficacy and adverse events 
occurrence, evaluated clinically, but without any functional or instrumental indicator (Dressler, 
2009). Similarly, Baricich et al. evaluated the efficacy and safety in terms of adverse events of high 
doses of onabotulinumtoxinA (up to 800 U with a mean of 676.9 ± 86.3 U) in stroke survivors through 
a clinical evaluation (Baricich et al., 2015). Lastly, Lee et al. compared the efficacy and safety of 
incobotulinumtoxinA with onabotuli- numtoxinA in treating periocular rhytides and masseteric 
hyper- trophy, showing no differences between the two molecules (Lee et al., 2014); however, the 
maximum dose used was far lower compared to those normally prescribed to treat post stroke 
spasticity.  
In light of these considerations, the aim of this study was to evaluate changes in HRV induced by 
high doses (>600 U) of incobotulinumtoxinA or onabotulinumtoxinA in spastic stroke patients over 
a 1-year period using a crossover study design. Moreover, we assessed the treatment safety by 
monitoring adverse events occurrence.  
 
2. Materials and methods  
2.1. Patients  
This work was a randomized, single blind, controlled crossover study. A total of 10 stroke survivors 
with spastic hemiplegia were consecutively enrolled at the Rehabilitation Unit of the University 
Hospital in Novara from September 2014 to January 2015. The inclusion criteria were: I) focal 
spasticity graded >=2 on Modified Ashworth Scale (Bohannon and Smith, 1987) at upper and lower 
limb muscles, requiring at least 600 incobotulinumtoxinA units; II) hemiplegia after ischaemic or 
haemorrhagic stroke documented by CT scan and/or available case history; III) age > 18 years.  
Exclusion criteria were: I) heart failure with NYHA >=3; II) previous diagnosis of cardiac arrhythmia; 
III) concomitant use of beta-blockers; IV) pace-maker implant; V) presence of fixed contractures at 
BoNT-A target muscles.  
 
2.2. Study design  
After the enrollment, patients were allocated to one of the two treatment arms by the use of a 
randomization scheme generated by software. Patients were then divided into two groups (A and B) 
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and entered the first part of the study. In this first part of the study, patients in group A were injected 
with incobotulinumtoxinA (NT 201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany) 
with a dilution of 100 units/2 mL of 0.9% sterile saline, while group B patients were injected with 
onabotulinumtoxinA (Botox®,Allergan, Irvine, CA, USA), 100 MU in 2 ml of 0.9% sterile saline. 
Patients in both groups were blinded to BoNT-A treatment type and received doses below 12 
units/Kg.  
After 6 months, the second part of the study started, and each group received the crossover 
intervention: group A patients were treated with onabotulinumtoxinA (Botox®, Allergan, Irvine, CA, 
USA, 100 MU in 2 ml 0.9%NaCl/H2O), whereas group B patients were treated with 
incobotulinumtoxinA (NT 201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany with a 
dilution of 100 units/2 mL of 0.9% sterile saline). The same target muscles and doses of the first part 
of the study were maintained. Study design is described in Fig. 1.  
 
 
 
Patients were blinded to BoNT-A treatment type during the whole study period. Each patient signed 
an informed consent to the treatment and the evaluations of this study. The local committee of our 
Hospital approved our protocol, which was conducted ac- cording to the principles of the Declaration 
of Helsinki.  
 
2.3. Assessment  
All patients in both groups performed a total of four ECG registrations of 30 min each. In the first 
part of the study, patients performed the ECG registration in the 24 h before BoNT-A injection 
(baseline, t0) and 10 days after the treatment (t1); similarly, in the second, crossover, part of the study, 
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they performed the ECG registration 24 h before the new BoNT-A injection and 10 days after the 
treatment. Each ECG recording was performed as described elsewhere (Invernizzi et al., 2015).  
Treatment safety was assessed by monitoring adverse events occurrence of any degree.  
Lastly, the following functional measures were recorded at baseline: Barthel Index (Shah et al., 1989), 
Motricity Index (MI) for upper and lower limbs (Collin and Wade, 1990), Functional ambulation 
category (FAC) (Collen et al., 1990).  
Data obtained from analogic ECG were processed with an A/D converter (micro 1401 CED© 
Cambridge Electronic Design, Cambridge, UK) and recorded on a PC by means of a data acquisition 
system (Spike2 v.5, CED) with a sampling rate of 3000 Hz. Guidelines were followed for time 
recordings, sampling rate and HRV analysis of electrocardiograms (Task Force, 1996). Artifacts and 
noise regions were removed, and, in case of premature beats, they have been manually corrected. 
Only the recordings that contained <1% of premature beats were considered.  
ECG's have been analysed by means of software called “Kubios HRV analysis”, originally created 
by Niskanen et al. (2004). In this study we considered both linear and non-linear HRV indexes 
(Buccelletti et al., 2012). A detailed description of all linear and non- linear HRV indexes used in this 
study can be found in the supplementary material of Invernizzi et al. (2015).  
 
2.4. Statistical analysis  
Statistical analysis was performed using the GraphPad 6 package, version 6.0 (GraphPad Software, 
Inc., San Diego, CA, USA). The patients were randomly assigned to one of the treatment arms using 
a randomization scheme generated by software with a 1:1 allocation and without blocks. Due to the 
small sample size, we supposed a non-gaussian distribution of variables.  
Differences between each variable in each group have been evaluated with Friedman's analysis of 
variance (ANOVA) and Dunn post hoc comparison was used to identify significant differences 
between mean values. Differences between single variables in different groups were evaluated with 
the Mann-Whitney U-test. A type I error (alpha) level of 0.05 was chosen.  
 
3. Results  
Demographic data of the enrolled patients, dose/kg and mean overall doses of onabotulinumtoxinA 
and incobotulinumtoxinA utilised are resumed in Table 1. As shown in Tables 2 and 3, none of the 
variables considered for time, frequency and non-linear domains showed any statistically significant 
changes after each BoNT- A injection in both Groups A and B at any evaluation time. Moreover, no 
statistically significant differences were found regarding each variable considered between the two 
groups. Lastly, one patient in each group experienced mild, self-limiting adverse events after the 
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treatment (pain at the injection site). In each case, adverse events were related to the injection 
procedure and spontaneously resolved without any intervention 15 min after treatment.  
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4. Discussion  
The results of this study show that high doses (>600 U) of incobotulinumtoxinA and 
onabotulinumtoxinA do not influence the autonomic drive directed to the heart in chronic hemiplegic 
spastic stroke survivors. These results are also confirmed if the two BoNT-A formulations are 
interchanged in a crossover design suggesting the potential absence of cumulative effects. Moreover, 
both the treatment with incobotulinumtoxinA and the treatment with onabotulinumtoxinA showed 
only one mild self-limiting adverse event in each group, related to the injective procedure and spon- 
taneously resolved.  
The results obtained in this study not only confirm the safety of incobotulinumtoxinA from a 
cardiovascular point of view, but also, for the first time, produce data about the autonomic heart 
modifications in stroke survivors with spasticity treated with high doses (>600 U) of 
onabotulinumtoxinA.  
In 2009, Dressler in a crossover prospective study converted patients previously treated with 
onabotulinumtoxinA to incobotulinumtoxinA and repeatedly injected them for 3 years, monitoring 
clinical efficacy and adverse events occurrence. The author did not find any difference in the efficacy, 
treatment duration and adverse events occurrence after changing the two drug formulations, 
suggesting a clinical equivalence of the two BoNT-A formulations (Dressler, 2009). Our results are 
somehow comparable with those obtained by Dressler, considering also the fact that all outcome 
measures related to safety in that study were obtained with an anamnestic evaluation only, without 
any instrumental objective measure. More recently, Mehnert et al. showed similar results observing 
onabotulinumtoxinA effects on cardiac function after intradetrusor injection, showing no HRV 
modifications after treatment (Mehnert et al., 2016). The absence of a relevant effect on the autonomic 
 50 
drive directed to the heart may have a clinical relevance in the treatment decision with high doses of 
BoNT-A in stroke survivors affected by cardiovascular comorbidities, in which a reduction in HRV 
is known to be able to increase the incidence of cardiovascular events (Task Force, 1996). Moreover, 
even in patients without known cardiac diseases, our results can limit the potential concerns about 
the use of BoNT-A at a dosage greater than 600 units.  
As underlined, only few studies in literature investigated the possible autonomic cardiovascular 
modifications induced by onabotulinumtoxinA, and with doses far lower than those utilised in our 
work. Lastly, the fact that these two drugs at the same dose in the same patients at different times 
induce the same modifications on HRV can in part explain the clinical results regarding efficacy and 
safety found by Dressler (2009). However, due to the low sample size, our data should be taken 
cautiously and for this reason further experience with high dose use of BoNT-A is needed.  
As a last consideration, our data suggest also, in line with the results obtained by Dressler, that the 
treatment with high doses of BoNT-A (both onabotulinumtoxinA and incobotulinumtoxinA) does not 
seem to produce any cumulative effect on HRV modifications and adverse events occurrence. Even 
though the overall study period involved only two BoNT-A injections, these data are consistent with 
previous studies of safety in multiple spasticity treatment performed with BoNT-A and give further 
elements about overall BoNT-A safety at high doses (>600 U) in hemiplegic stroke survivors 
(Santamato et al., 2013; Baricich et al., 2015).  
This study has several limitations: the first is the low sample size; the second is the overall study 
duration (1 year) that hinders the possibility to evaluate long-term modifications induced by multiple 
BoNT-A injections.  
 
5. Conclusions  
In conclusion, this study confirms the safety of incobotulinumtoxinA at doses up to 12 units/kg 
regarding the autonomic heart drive modifications and adverse events occurrence in adult stroke 
hemiplegic spastic patients. Moreover, for the first time in literature, this study shows the same results 
in terms of safety of onabotulinumtoxinA. Lastly, multiple administrations of BoNT-A at high doses 
in adult hemiplegic patients do not seem to induce any cumulative effect. However, further experience 
with high doses of BoNT-A is needed in order to confirm these results and, in particular, for the 
clinical use of these two BoNT-A formulations in patients with cardiovascular comorbidities.  
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Discussion 
 
Current evidence coming from published literature suggests that higher doses of BoNT-A are 
efficacious in reducing spasticity of the upper and lower limbs after stroke, with rare occurence of 
mild adverse effect.  
Although systemic BoNT-A toxicity is a rare event and as such not necessarily fatal, fear of systemic 
toxicity is still the most vigorous concern against application of increased BoNT-A doses.  
Previous neurophysiological studies demonstrated that neuromuscular transmission could be 
temporally abnormal also in muscles distant from the target muscles: however, these findings were 
not related to any clinical dysfunction. In addition, cumulative data suggest that high doses (>600 U) 
of incobotulinumtoxinA and onabotulinumtoxinA do not influence the cardiovascular activity of the 
autonomic nervous system in chronic hemiplegic spastic stroke survivors, showing a satisfactory 
safety profile. On the other hand, at present time, there is no evidence with respect to doses of 
abobotulinumtoxinA higher than 1500, even if Hesse and colleagues [1995] reported good tolerability 
after administration of 2000 U.  
Moreover, as described in previous studies, it must be pointed out that generalized weakness can 
occur also for recommended doses of BoNT-A [Bakheit et al, 1997].  
 
A possible explanation is that local and systemic diffusion of BoNT could depend on several factors: 
injection technique, volume, dilution, needle size, hematogenous transport and other physical factors.  
For example, the use of ultrasonography to identify target muscles may improve accuracy of needle 
placement, avoiding injection into vascular structures and reducing the potential risk of systemic 
diffusion of BoNT-A [Henzel et al, 2010]. Moreover, this technique can improve clinical outcome 
both in upper and lower limb PSS [Picelli et al, 2014; Santamato et al, 2014].  
 
Another relevant issue related to the risk of side effects regards the dilution of BONT-A.  
Current guidelines on adult dosing of BoNT-A recommend a maximum of 1 ml per site, except in 
selected situations [Mayer and Simpson, 2010]. This raises the possibility that higher doses or 
volumes of BoNT-A could saturate local cholinergic nerve terminals, allowing unbound toxin to 
spread to the adjacent structures or the blood stream. In particular, attention is due in case of high 
doses of BoNT-A and/or high volumes injected into the proximal muscles across the midline in order 
to avoid the risk of contralateral weakness, as reporteded by Thomas and Simpson [2012].  
 
In addition, it should be pointed out that, despite the reduction of severe spasticity, there is limited 
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evidence that treating patients with elevated BoNT-A doses in the upper and lower limbs is related to 
significant functional improvement. However, this observation could be related to several 
possibilities.  
First of all, it is well known that in the case of severe spasticity the improvement in active performance 
is sometimes difficult to acquire; however, in many neurological conditions high doses should be 
considered in order to obtain a reduction of muscle tone (especially in the adductor and calf muscles) 
with significant improvement in hygiene, gait, and balance.  
In addition, these observations are reflected in the paucity of studies able to identify the true 
correlation between spasticity and disability [Ada et al, 1998. Pradon et al, 2013]. On the other hand, 
different studies demonstrated the efficacy of spasticity treatment in passive and active functional 
improvement of patients [Ward et al, 2014]. 
However, in a study examining disability in post stroke spasticity patients, treatment of spasticity that 
was only moderately severe according to the Ashworth Scale resulted in notable improvements in 
performing activities of daily living, as indicated by a patient-assessed composite disability scale 
[Bhakta BB et al, 2000]. In light of these considerations, a Delphi Panel consensus [Zorowitz et al, 
2017] recently proposed a screening tool in order to evaluate the spasticity in need of treatment.  
However, the impact of spasticity on a subject might be characterized by the degree of limitation in 
performing functional tasks and by the impact on well-being and life satisfaction, which may not be 
indicated by objective score results but are demonstrated by patient-reported outcome measures 
[Sunnerhagen and Francisco, 2013; Baricich et al, 2016]. 
A possible explanation of these controversial observations could be related to problems occurring in 
patient–provider communication, and its role in post-stroke spasticity rehabilitation.  
In a context of patient-centered health care, it could address the holistic experience of illness from 
patient’s perspective [Sunnerhagen and Francisco, 2013; Leach et al, 2010].  
In addition, it should be considered that PSS also has an afferent, sensory component, which might 
be related to some differences in the sensations described by patients [Baricich et al, 2016]. In fact, 
it is well known that proprioceptive afferent information coming from mechanoreceptors in joints, 
muscles, tendons and stretch-sensitive receptors in the skin, together with efferent motor signals, can 
play a key role in postural schema understood as dynamic representations of body posture. Moreover, 
the sense of body ownership, too, is presumably developed using sensory information, as recently 
described by Walsh and colleagues [2011] who demonstrated that non-tactile proprioceptive cues 
might contribute to this sense.  
On these bases, we hypothesized a patient-reported screening tool able to identify the functional 
impact of spasticity after stroke. This tool is potentially fit to be used in routine clinical practice in 
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order to improve an early detection of functionally relevant spasticity and ameliorate patients’ care.  
An expert panel identified a 15-items questionnaire which investigates the clinical impact of 
spasticity in activities of daily living (ADL), named SPasticity Questionnaire in Real life (SPQR) 
(see Appendix). The score ranges from 0 (no clinical impact) to 45 (very significant impact in the 
whole panel of ADL). The tool is designed on the basis of the Rasch measurement model, a 
probabilistic mathematic modelling technique, used to assess the psychometric properties of outcome 
measures; it examines wider attributes, analyzing the item’s performances in terms of relevance, 
usefulness for measuring the underlying construct, redundancy and appropriateness [Tesio, 2003].  
We preliminarly tested SPQR in a population of chronic stroke survivors affected by spasticity, 
according to the recommended guidelines (unpublished data). SPQR showed an excellent internal 
consistency (Cronbach’s alpha 0.95), and good reproducibility and validity [Pearson’s cofficient 0.76 
p<0.05; Kappa coefficient 0.76 (95% CI 0.61-0.91); Intraclass Correlation Coefficient 0.89 (95% CI 
0.71- 0.96)]. In addition, at T2 SPQR showed a significant score variation for upper and lower limb 
functional improvement, according to the changes in muscle tone evaluated by Modified Ashworth 
Scale. To the best of our knowledge, this is the first tool specifically designed to evaluate the 
functional implications of spasticity and the clinical impact of its treatment on patients’ outcome.  
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Conclusions and future perspectives 
 
The evidence coming from published studies suggests that use of doses of BoNT-A higher than those 
reported in product labels could be considered as a safe therapeutic option to reduce multifocal or 
generalized post stroke spasticity in selected patients.  
However, it must be pointed out that the clinicians have to carefully define the clinical goal before 
starting with BoNT-A treatment. In addition, based on current evidence, they must consider all the 
factors which could affect the safety profile of BoNT-A, such as injection technique, dose and 
dilution.  
Further evidence is mandatory to confirm higher doses of BoNT-A as a safe and effective therapeutic 
option for the treatment of post stroke spasticity.  
In particular, it should be pointed out the potential role of higher doses of BoNT-A in order to improve 
the functional outcome of patients affected by PSS. As previously stated, it should be noted that the 
impact of PSS on limitations in ADL, wellbeing and life satisfaction may not be indicated by 
quantitative scores but could be demonstrated by patient-reported outcome measures such as SPQR 
questionnaire.  
In light of these considerations, further research is also required in order to confirm the validity and 
reliability of these tools.  
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Appendix  
 
SPQR – SPasticity Questionnaire in Real Life 
 
 
Istruzioni: il seguente questionario riguarda le Sue capacità di eseguire alcune azioni con la parte del 
corpo colpita dall’ictus. Risponda a ogni domanda selezionando una delle quattro voci.  
La spasticità è la rigidità dei muscoli dovuta all’ictus e non la debolezza dei muscoli. Nell'ultima 
settimana quanto la sua spasticità ha influenzato le seguenti attività quotidiane?  
 
 
 
 
 
 
 
